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ABSTRACT
An exact classification of precancerous stages of colorectal polyps might improve 
therapy and patients´ outcome. Here we investigate the association between grade 
of dysplasia and Matrix metalloproteinase-13 (MMP-13) expression in 137 biopsies 
from patients with cancerous and non-cancerous colorectal adenomas. A reproducible 
staining procedure for histologic MMP-13 analysis in routinely fixed colorectal biopsy 
specimens has been established. A newly adopted immunoreactive scoring system 
for MMP-13 was demonstrated as reliable readout.
The strength of the association between pathologic stage and immunoreactive 
MMP-13 scoring emphasizes its eligibility for diagnosis in precancerous colorectal 
lesions.
INTRODUCTION
Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer in the world [1]. Based on 18 studies, 
the pooled prevalence of adenomas, colorectal cancer, 
non-advanced adenomas, and advanced adenomas was 
30.2%, 0.3%, 17.7%, and 5.7%, respectively [2]. In a 
population-based case-control study, the risk of CRC was 
strongly reduced after colonoscopy for any indication [3]. 
A key point for improving the survival rate is the correct 
diagnosis and treatment at an early stage [4].
Most cases of colorectal carcinogenesis are 
characterized by enhanced expression of MMP-3, -7, 
and -13 [5]. MMP-7 and MMP-13, which are expressed 
primarily on the tumor cell surface, are elevated in 
inflammatory bowel disease [6]. Studies indicate 
that expression of MMP-13 is closely related to the 
development and progression of colorectal cancer [7–9]. 
Immunoreactivity to MMP-13 was identified in 91% and 
localized to tumor cells. A high MMP-13 staining score 
showed a trend towards poorer survival [7] and a high 
MMP-13 expression level is associated with a high rate 
of liver metastasis [9]. Furthermore, positive MMP-13 
expression was related to bad prognosis and early relapse 
[7, 10]. Thus, MMP-13 could be a useful indicator for 
tumor behavior and prognosis of CRC.
Our aim was to determine whether MMP-13 
expression in colorectal adenomas and carcinomas is 
useful for a concise and accurate diagnosis. Therefore we 
assessed the association between grade of dysplasia and 
MMP-13-expression. The characterization of the CRC-
specific biomarker MMP-13 should facilitate objective and 
early detection of high grade adenomas and carcinomas.
RESULTS
MMP-13 expression was assessed in 137 biopsy 
samples from 105 patients with colorectal adenomas and 
colorectal cancer (Table 1).
Mean age was 67 ± 13 years and 34 (32.4%) patients 
were female. Samples included 15 (12.3%) hyperplastic 
adenomas, 64 (52.5%) low grade adenomas, 20 (16.4%) 
high grade adenomas and 23 (18.9%) carcinomas. 
Following histological types were found: 15 (12.3%) were 
hyperplastic, 37 (30.3%) were tubular and 70 (57.4%) 
tubulovillous.
The MMP-13 expression increased with pathologic 
stage of the (pre-) cancerous mucosal lesions (Figure 1). 
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In low grade adenomas we detected a weak MMP-
13 staining in 45% of the samples. In high grade adenomas 
and colorectal cancer MMP-13 was located with a 
moderate and strong staining. 9 (30%) of 30 (30%) of 
healthy controls (15 hyperplastic adenomas and 15 tumor-
free surgical margins) and 32 (50%)  of 64 (50%) lowgrade 
samples were totally negative for MMP-13, while none 
of the high grade adenomas and colorectal carcinoma 
was totally negative for MMP-13. MMP-13 expression 
was evaluated using a newly adopted immunoreactive 
score (IRS, Figure 2A) [11] increasing with the grade of 
dysplasia.
MMP-13 IRS increased significantly in low grade 
adenomas compared to healthy controls (p = 0.008), in 
high grade adenoma compared to low grade adenoma 
(p < 0.001), whereas the further increase in carcinomas did 
not reach statistical significance (p = 0.059; Figure 2B). 
Figure 2C shows the diagnostic value (ROC-curve) 
of MMP-13 IRS for discrimination between healthy 
and low grade adenoma vs. high grade adenoma and 
carcinoma with an area under the curve of 96.28% (95% 
CI 93.7%–98.9%, p < 0.001), indicating a very high 
diagnostic accuracy. MMP-13 IRS > 2.5 (ROC 97.67% 
sensitivity) comprises high grade adenoma and carcinoma. 
Considering the prevalence of high grade adenoma and 
carcinoma, the positive predictive value is 73.64%. In turn 
84.04% (specificity) of biopsies are correctly identified as 
healthy or containing low grade adenoma. The negative 
predictive value is 98.75%.
MMP-13 protein expression assessed by Western 
blotting (Supplementary Figure S1), increased with the 
degree of pathological stage. In healthy tissue and low 
grade adenomas only weak signals could be detected, 
whereas in high grade adenoma and carcinoma stronger 
signals and bands of activated MMP-13 appeared. These 
findings correlate with MMP-13 IRS. β-actin loading 
control indicated equal loading.
Double staining of MMP-13 and cellular markers 
revealed a co-localization of MMP-13 with CK20 
in epithelia, vWF in endothelial cells, and Vimentin 
Table 1: Demographic and clinical data of the cohort, n = 105
Demographics n percentage/ total
Women 34 32.4%
Men 71 67.6%
Age
Mean 66.7
SD 13.4
Histological Controls
Tumor free resection margins 15
Histiologic type
tubular 37 30.3%
tubulovillous 70 57.4%
hyperplastic 15 12.3%
Dysplasia
hyperplastic 15 12.3%
lowgrade 64 52.5%
highgrade 20 16.4%
carcinoma 23 18.9%
Localisation
Rectum 25 20.5%
Rektosigmoid 5 4.1%
Sigmoid Colon 28 23.0%
Descending Colon 10 8.2%
Left colic flexure 0 0.0%
Transverse Colon 8 6.6%
Right colic flexure 10 8.2%
Ascendic Colon 23 18.9%
Cecum 13 10.7%
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in fibroblasts (Supplementary Figure S2A). No co-
localisation appeared in B-cells, T-cells, macrophages and 
monocytes (Supplementary Figure S2B).
DISCUSSION
The outcome of CRC depends on the extent of 
local and particularly metastatic tumor spread. MMPs are 
considered to be important in facilitating tumor invasion 
and spread. The expression of MMP-13 seems to be 
closely related to development, invasion, and progression 
of colorectal cancer [8, 9].
We demonstrate that MMP-13 expression, 
quantitatively assessed by a newly adopted IRS and 
verified by Western blotting, increased with pathological 
stage of adenoma and carcinoma development. The 
high diagnostic accuracy demonstrates the quality 
of this IRS for identification of low and high grade 
adenomas as well as CRC. Moreover, in high grade 
adenoma and cancer samples bands of activated 
MMP-13 point out functionalization of MMP-13 
during cancerogenesis (Supplementary Figure S1). It 
has been shown before that high levels of MMP-13 
correlate with higher rates of liver metastasis, a bad 
prognosis, and early relapse [9, 10]. Thus, MMP-13 IRS 
could also be helpful to predict metastatic behaviour, 
prognosis, and relapse at an early stage of cancerous and 
precancerous colorectal adenoma, which is definitely 
not accessible by conventional histology. Especially 
the strong increase in MMP-13 IRS from low to high 
grade adenoma defines an early timepoint of beneficial 
MMP-13 staining as early predictive cancer marker. 
Nevertheless, to ensure the diagnostic value of MMP-13 
IRS in predicting cancer behaviour at this stage long-term 
follow-up studies are necessary. In previous studies we 
demonstrated enhanced expression of tumor-associated 
MMPs (MMP-2, MMP-7, MMP-9, and MMP-13) in 
native, unfixed, but cryo-conserved samples of patients 
with inflammatory bowel disease by qRT-PCR, ELISA, 
and immunofluorescence [6, 12]. The current study was 
designed to establish a translational protocol with regard 
to a reproducible, specific, and sensitive analysis of the 
tumor-associated MMP-13 in routinely assessed biopsy 
specimens from precancerous colorectal lesions. For the 
present study, histologically defined cancerous and non-
cancerous colorectal adenomas but not inflammatory 
samples were included. Therefore, validation of MMP-
13 IRS for IBD inflammatory bowel disease should be 
enrolled in another study.
MMP-13 is produced by fibroblasts [13], 
synoviocytes [14], endothelial cells [15], Kupfer cells 
[16], and more. We demonstrated MMP-13 expression in 
fibroblasts, endothelial and epithelial cells. As the amounts 
of MMP-13 clearly depend on the state of dysplasia, 
MMP-13 could be a useful marker to discriminate the 
different critical stages of dysplasia. 
Up to now no differentiation of serrated adenomas 
and flat adenomas was conducted due to the limited study 
collective. Furthermore, subgroups were not differentiated 
for familiar risk factors or left and right sided lesions.
In conclusion, MMP-13 IRS represents a suitable 
method to assess pathologic grade of precancerous and 
cancerous colorectal lesions. MMP-13 has been identified 
as an excellent marker of high grade IEN and CRC, and 
may thus be applied for prognostic stratification. The 
identification of cellular MMP-13 sources offers a basis 
for targeted therapeutic modulation in CRC.
Figure 1: Increasing expression of MMP-13 in colonic adenoma-carcinoma sequence. Immunohistochemical staining for 
MMP-13 (brown) in low and high grade adenoma, healthy controls, and carcinoma demonstrates a correlation between neoplastic grade and 
MMP-13 expression. Representative micrographs are shown. Nuclei are stained blue. Scale bars: 100 µm, upper panels 100× and 25 µm, 
lower panels 400×. 
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MATERIALS AND METHODS
Patients
The study was approved by the local ethics 
committee (Approval No. AZ 116/12). From June 2013 
to January 2015 105 patients were enrolled for the study, 
the patient samples were collected by the Department 
of Pathology. Patients who underwent endoscopy 
with polypectomy or surgery had been included. 
A series of 137 biopsies from colorectal adenomas and 
colorectal cancer from 105 patients were analyzed. The 
biopsy material was fixed and examined concerning to 
hyperplastic, low or high grade dysplasia histologically 
as a matter of routine by two independent pathologists. 
Immunohistochemically staining of MMP-13 was 
performed and semi-quantitatively evaluated according to 
a novel immunoreactive score (IRS).
Immunoreactive score (IRS)
The stained specimens were analyzed using a 
modified immunoreactive score adapted to Remmele et al. 
[11] Briefly, the staining was graded (grade: 0, negative; 1, 
weak; 2 moderate; 3 strong) and the percentage of positive 
stained cells were counted (count: 0, 0%; 1, < 10%; 2, 
11–50%; 3, 51–80%; 4, > 81%). IRS is defined as grade X 
count and thus, runs the gamut from 0 to 12.
Figure 2: Quantitative assessment of MMP-13 by Immunoreactive Scoring. (A) Schematic workflow for assessment of 
IRS. (B) Immunoreactive scoring of MMP-13 discriminated between low- and high grade adenoma. §p < 0.01 in comparison to control. 
#p < 0.001 in comparison to low grade adenoma. Data are presented in box-and-whisker-plots. Values deviating from the box by 1.5- to 
3- fold interquartile range were defined as outliers (o). Extreme values (*) with a distance of more than 3 box-lengths were not considered 
for statistical analysis. (C) In total patient population, ROC analysis for the diagnostic accuracy of IRS for pathologic decision healthy or 
low grade vs. high grade adenoma or carcinoma was performed: AUC of ROC = 0.963, 95% CI 0.94–0.99, p < 0.001.
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Immunohistochemistry
Paraffin sections were dewaxed, unmasked by 
boiling in citrate buffer at pH = 6 for 10 minutes, and 
endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide solution for 30 min. Protein blocker 
was used for 1 hour to inhibit non-specific antigen-
antibody reactions (2.5 % normal horse serum; Vector 
Laboratories, Burlingame, USA).
Immunostaining was performed using specific 
antibodies for detection of MMP-13 (1:100, goat anti 
MMP-13 polyclonal IgG, R&D Systems, Minneapolis, 
USA) and suitable secondary antibodies (Impress 
Reagent Kit anti-goat-Ig Vector, Vector Laboratories, 
Burlingame, USA). For color reaction, the slides were 
stained with VIP Substrate kit for peroxidase (Vector 
Laboratories) and counterstained with methyl green. 
A violet precipitate in the cytoplasm indicates a positive 
reaction. Antibodies for CD3 as T-cell marker (rabbit anti 
CD3 polyglonal IgG, Abcam, Cambridge, UK), CD14 
as monocyte marker (rabbit anti CD14 polyclonal IgG, 
Progen, Heidelberg, Germany), CD20 as B-cell marker 
(goat anti CD 20 polyclonal IgG, Santa Cruz, Dallas, 
USA), CD68 as marker for macrophages (mouse anti CD 
68 purified IgG, Bio Legend, Fell, Germany), CK20 as 
colorectal epithelial marker (rabbit anti CK 20 polyclonal 
IgG, Protein tech, Chicago, USA), Vimentin as fibroblast 
marker (mouse anti Vimentin Ab-2 monoclonal IgG, 
Thermo Fischer, Frankfurt aM, Germany), and vWF 
as marker for endothelia (rabbit anti vWF polyclonal 
IgG, Dako, Hamburg, Germany) were used for double 
staining to detect cellular sources of MMP-13 expression. 
Secondary staining was performed with DAB Substrate Kit 
for Peroxidase (Vector Laboratories) and counterstained 
with methyl green. A brown reddish color was shown. 
Co-localization is marked by a mixed color. For negative 
controls equally concentrated unspecific isotype IgG were 
applied instead of primary antibodies.
Protein extraction
Protein extraction from formalin-fixed paraffin 
embedded sections was performed as described before [17].
Western blotting
Western blotting was performed as described 
elsewhere, [18] using antibodies specific for MMP-
13 (Santa Cruz Biotechnology) and rabbit anti-ß-actin 
(# 4970, Cell Signaling, Leiden, Netherlands) detection.
Statistical analysis
Statistical analysis was performed with SPSS 
version 22 and R version 3.1.3. The IRS of hyperplastic, 
low grade, high grade adenomas, and colorectal carcinoma 
were compared by Kruskal-Wallis Test, testing whether 
the medians of IRS are the same in all groups. Pairwise 
comparison of IRS was conducted using Mann-Whitney´s 
U-test and Bonferroni-Holm correction for multiple testing. 
Diagnostic performance was evaluated using 
receiver operating characteristic (ROC) curve analysis. 
Confidence interval (CI) for the area under the curve 
(AUC) was calculated using DeLong’s method. The best 
threshold for diagnostic purposes was determined using 
Youden’s J statistic. ROC analyses were performed with 
the pROC R-package, version 1.8. [19].
CONFLICTS OF INTEREST
The authors declare that no conflicts of interest exist.
GRANT SUPPORT
This work was funded by the Manfred Stolte 
Stiftung, Germany.
REFERENCES
 1.  Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 
Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.
 2.  Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, 
Hemmelgarn BR. Prevalence of adenomas and colorectal 
cancer in average risk individuals: a systematic review 
and meta-analysis. Clin Gastroenterol Hepatol. 2009; 
7:1272–1278.
 3.  Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, 
Hoffmeister M. Reduced risk of colorectal cancer up 
to 10 years after screening, surveillance, or diagnostic 
colonoscopy. Gastroenterology. 2014; 146:709–717.
 4.  Fitzpatrick-Lewis D, Ali MU, Warren R, Kenny M, 
Sherifali D, Raina P. Screening for Colorectal Cancer: A 
Systematic Review and Meta-Analysis. Clin Colorectal 
Cancer. 2016.
 5.  Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S. 
Simultaneous determination of matrix metalloproteinase 
(MMP)-7, MMP-1, -3, and -13 gene expression by 
multiplex PCR in colorectal carcinomas. Int J Colorectal 
Dis. 2004; 19:518–524.
 6.  Rath T, Roderfeld M, Graf J, Wagner S, Vehr AK, Dietrich C, 
Geier A, Roeb E. Enhanced expression of MMP-7 and 
MMP-13 in inflammatory bowel disease: a precancerous 
potential? Inflamm Bowel Dis. 2006; 12:1025–1035.
 7.  Leeman MF, McKay JA, Murray GI. Matrix 
metalloproteinase 13 activity is associated with poor 
prognosis in colorectal cancer. J Clin Pathol. 2002; 
55:758–762.
 8.  Miao C, Ren Y, Chen M, Wang Z, Wang T. Microcystin-
LR promotes migration and invasion of colorectal cancer 
through matrix metalloproteinase-13 up-regulation. Mol 
Carcinog. 2015; 55:514–524.
Oncotarget73557www.impactjournals.com/oncotarget
 9.  Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, 
Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, 
Kunisaki C, Shiozawa M, Morinaga S, et al. Overexpression 
of MMP-13 gene in colorectal cancer with liver metastasis. 
Anticancer Res. 2010; 30:2693–2699.
10.  Yan Q, Yuan Y, Yankui L, Jingjie F, Linfang J, Yong P, Dong H, 
Xiaowei Q. The Expression and Significance of CXCR5 
and MMP-13 in Colorectal Cancer. Cell Biochem Biophys. 
2015; 73:253–259
11.  Remmele W, Stegner HE. [Recommendation for 
uniform definition of an immunoreactive score (IRS) for 
immunohistochemical estrogen receptor detection (ER-
ICA) in breast cancer tissue]. Pathologe. 1987; 8:138–140.
12.  Rath T, Roderfeld M, Halwe JM, Tschuschner A, Roeb E, 
Graf J. Cellular sources of MMP-7, MMP-13 and MMP-
28 in ulcerative colitis. Scand J Gastroenterol. 2010; 
45:1186–1196.
13.  Mariani TJ, Sandefur S, Roby JD, Pierce RA. Collagenase-3 
induction in rat lung fibroblasts requires the combined 
effects of tumor necrosis factor-alpha and 12-lipoxygenase 
metabolites: a model of macrophage-induced, fibroblast-
driven extracellular matrix remodeling during inflammatory 
lung injury. Mol Biol Cell. 1998; 9:1411–1424.
14.  Wernicke D, Schulze-Westhoff C, Brauer R, Petrow P, 
Zacher J, Gay S, Gromnica-Ihle E. Stimulation of 
collagenase 3 expression in synovial fibroblasts of 
patients with rheumatoid arthritis by contact with a three-
dimensional collagen matrix or with normal cartilage when 
coimplanted in NOD/SCID mice. Arthritis Rheum. 2002; 
46:64–74.
15.  Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, 
Tulchinsky E, Lukanidin E, Ambartsumian N. 
Extracellular S100A4(mts1) stimulates invasive growth 
of mouse endothelial cells and modulates MMP-13 matrix 
metalloproteinase activity. Oncogene. 2004; 23:5487–5495.
16.  Hironaka K, Sakaida I, Matsumura Y, Kaino S, 
Miyamoto K, Okita K. Enhanced interstitial collagenase 
(matrix metalloproteinase-13) production of Kupffer cell 
by gadolinium chloride prevents pig serum-induced rat 
liver fibrosis. Biochem Biophys Res Commun. 2000; 
267:290–295.
17.  Kawashima Y, Kodera Y, Singh A, Matsumoto M, 
Matsumoto H. Efficient extraction of proteins from 
formalin-fixed paraffin-embedded tissues requires higher 
concentration of tris(hydroxymethyl)aminomethane. Clin 
Proteomics. 2014; 11:4.
18.  Kampschulte M, Stockl C, Langheinrich AC, Althohn U, 
Bohle RM, Krombach GA, Stieger P, Churin Y, Kremer S, 
Dierkes C, Rath T, Roeb E, Roderfeld M. Western 
diet in ApoE-LDLR double-deficient mouse model of 
atherosclerosis leads to hepatic steatosis, fibrosis, and 
tumorigenesis. Lab Invest. 2014; 94:1273–1282.
19.  Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, 
Sanchez JC, Muller M. pROC: an open-source package 
for R and S+ to analyze and compare ROC curves. BMC 
Bioinformatics. 2011; 12:77.
